Summary
Experimental chronic renal insufficiency (produced by 5/6 ablation of renal parenchyma) is associated with changes in the kinetics of oral (intragastric) cyclosporine A (CyA). Compared with animals with intact renal parenchyma, significantly lower levels of CyA are reached under these conditions. The factors resonsible for reduced CyA availability under these conditions have not yet been identified.
Similar content being viewed by others
References
Kahan B.D., Kramer W.G., Wideman S.M. et al. (1986): Demographic factors affecting the pharmacokinetics of cyclosporine estimated by radioimmunoassay. Transplant. Proc., 41, 459–464.
Follath F., Wenk M., Vozeh S. (1983): Intravenous cyclosporine kinetics in renal failure. Clin. Pharmacol. Ther., 34, 638.
Buckart G.J., Starzl T.E., Venkataramenan R. et al. (1986): Excretion of cyclosporine and its metabolites in human bile. Transplant. Proc., 18 (Suppl 5), 46–49.
Grevel J. (1988): Significance of cyclosporine pharmacokinetics. Transplant. Proc., 20 (Suppl. 2), 428–434.
Bohdanecká M., Schück O., Petrásek R. et al. (1995): Experimental modeling of the effect of uremia on cyclosporin A bioavailability. Int. J. Clin. Pharmacol. Ther., 33, 61.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schück, O., Bohdanecká, M., Šedivý, J. et al. Changes in cyclosporine A kinetics after experimental reduction of renal parenchyma. European Journal of Drug Metabolism and Pharmacokinetics 22, 207–209 (1997). https://doi.org/10.1007/BF03189808
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF03189808